



Contacts:

Investors

EVC Group

Douglas Sherk, 415-896-6820

Jennifer Beugelmans, 646-201-5447

Media

EVC Group

Jen Saunders

646-201-5431

FOR IMMEDIATE RELEASE

Pharsight Expands Global Consulting Services Teams

*New Hires and Expanded Internship Program Strengthen
Strategic Consulting Services, Reporting and Analysis Staff in Europe and Canada*

MOUNTAIN VIEW, Calif., October 15, 2007 – Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced the expansion of its scientific consulting services practices with three new hires. Pharsight has also expanded its internship program, which is designed to foster knowledge of modeling and simulation amongst graduate students in a variety of scientific disciplines.

Pharsight has hired Lars Lindbom, Ph.D., as a senior associate scientist in its Strategic Consulting Services (SCS) group, based in Europe. Dr. Lindbom joins Pharsight from Uppsala University's department of Pharmaceutical Biosciences in Sweden, where he held a postdoctoral research fellowship sponsored by Pfizer. He also served as a bioinformatics software systems developer within the discovery research organization at AstraZeneca. Dr. Lindbom has broad experience with population pharmacokinetic and pharmacodynamic (PK/PD) modeling and pharmacometric method development, with an emphasis in computer-intensive statistical methods.

Dr. Lindbom holds a Ph.D. from Uppsala University's department of Pharmaceutical Biosciences, within the National Network in Drug Development, Swedish Foundation for Strategic Research. Dr. Lindbom has authored or co-authored several original research articles in the field of pharmacostatistical modeling and has given invited presentations on Perl-speaks-NONMEM (PsN), a collection of computer programs aiding in the development of non-linear mixed effects models using NONMEM, to which he was a developer and remains an active contributor.

Pharsight's recently launched Reporting and Analysis Services (RAS) business unit has added a PK scientist in response to increased global demand for the group's PK/PD analysis and reporting services. The RAS team has also added a Quality Assurance Inspector to support delivery of high quality, regulatory-compliant clinical study analyses and reports for new drug approval. Since its launch in May 2007, the RAS unit has more than tripled its staff and has plans to expand its facilities in Montreal, Canada. In addition, the RAS unit has accepted into its internship program a student working towards a Ph.D. in Pharmaceutical Sciences at the University of Montreal.

“The addition of new expert staff in both the SCS and RAS business units will further enhance our ability to address the full spectrum of client needs in modeling and simulation,” said Shawn O’Connor, president, chief executive officer and chairman of Pharsight. “Lars brings to SCS a wealth of expertise in the area of PK/PD modeling and advanced statistical methods. The addition of yet another talented, highly experienced scientist in the SCS group will help us meet the growing demand for applying model-based drug development approaches to support our client’s decision-making processes.”

“In addition to the expansion of the SCS team, we have continued to grow our RAS group’s capabilities by bringing on new talent,” continued Mr. O’Connor. “Requirements for regulatory-compliant analysis and reporting of PK/PD data to support new drug submissions has driven new customer demand for our RAS offering. We are pleased to extend Pharsight’s internship program to cover our entire consulting services practice, which provides talented Ph.D. students with opportunities to work on projects and gain in-depth modeling and simulation expertise. We look forward to contributions from our newest colleagues that will further enhance the services that we provide to our clients.”

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at <http://www.pharsight.com>.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.